Invention Grant
- Patent Title: HLA class II-restricted T cell receptors against mutated RAS
-
Application No.: US16135231Application Date: 2018-09-19
-
Publication No.: US11306132B2Publication Date: 2022-04-19
- Inventor: Rami Yoseph , Paul F. Robbins , Steven A. Rosenberg
- Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Applicant Address: US MD Bethesda
- Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Current Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Current Assignee Address: US MD Bethesda
- Agency: Leydig, Voit & Mayer, Ltd.
- Main IPC: C07K14/725
- IPC: C07K14/725 ; A61K35/17 ; G01N33/574 ; A61K38/17 ; A61P35/00 ; C12N15/62 ; C07K14/82
Abstract:
Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for mutated Kirsten rat sarcoma viral oncogene homolog (KRAS) presented by a human leukocyte antigen (HLA) Class II molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
Public/Granted literature
- US20190085046A1 HLA CLASS II-RESTRICTED T CELL RECEPTORS AGAINST MUTATED RAS Public/Granted day:2019-03-21
Information query
